Abstract
The pathology of more than 40 human degenerative diseases is associated with fibrillar proteinaceous deposits called amyloid. Collectively referred to as protein deposition diseases, many of these affect the brain and the central nervous system. In many cases the amyloid deposits are extracellular and are found associated with newly identified abundant extracellular chaperones (ECs). Evidence is discussed which suggests an important regulatory role for ECs in amyloid formation and disposal in vivo. This is emerging as an exciting field. A model is presented in which it is proposed that, under normal conditions, ECs stabilize extracellular misfolded proteins by binding to them, and then guide them to specific receptors for uptake and subsequent degradation. In this scenario, EC receptors are a critical part of a quality control system which protects the brain against dangerously hydrophobic proteins/peptides. However, it also appears possible that in the presence of a high molar excess of misfolded protein, such as might occur during disease, the limited amounts of ECs available may actually exacerabate pathology. Further advances in understanding of the mechanisms that control extracellular protein folding are likely to identify new strategies for effective disease therapies
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adler, V. and Kryukov, V. (2007). Serum macroglobulin induces prion protein transition. Neurochem. J. 1, 43–52.
Ambati, J., Anand, A., Fernandez, S., Sakurai, E., Lynn, B. C., Kuziel, W. A., Rollins, B. J. and Ambati, B. K. (2003). An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat. Med. 9, 1390–7.
Aoyagi, T., Wada, T., Kojima, F., Nagai, M., Harada, S., Takeuchi, T., Isse, K., Ogura, M., Hamamoto, M., Tanaka, K. and et al. (1992). Deficiency of fibrinolytic enzyme activities in the serum of patients with Alzheimer-type dementia. Experientia 48, 656–9.
Aquilina, J. A. and Robinson, C. V. (2003). Investigating interactions of the pentraxins serum amyloid P component and C-reactive protein by mass spectrometry. Biochem. J. 375, 323–8.
Arelin, K., Kinoshita, A., Whelan, C. M., Irizarry, M. C., Rebeck, G. W., Strickland, D. K. and Hyman, B. T. (2002). LRP and senile plaques in Alzheimer’s disease: colocalization with apolipoprotein E and with activated astrocytes. Brain Res. Mol. Brain Res. 104, 38–46.
Arispe, N., Rojas, E. and Pollard, H. B. (1993). Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc. Natl. Acad. Sci. U.S.A. 90, 567–71.
Aruga, E., Ozasa, H., Teraoka, S. and Ota, K. (1993). Macromolecules that are colocalized with deposits of beta 2-microglobulin in hemodialysis-associated amyloidosis. Lab. Invest. 69, 223–30.
Ashton, A. W., Boehm, M. K., Gallimore, J. R., Pepys, M. B. and Perkins, S. J. (1997). Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses. J. Mol. Biol. 272, 408–22.
Bajari, T. M., Strasser, V., Nimpf, J. and Schneider, W. J. (2003). A model for modulation of leptin activity by association with clusterin. FASEB J. 17, 1505–7.
Baltz, M. L., De Beer, F. C., Feinstein, A. and Pepys, M. B. (1982). Calcium dependant aggregation of human serum amyloid P component. Biochim. Biophys. Acta 701, 229–36.
Barrett, A. J. (1981). Alpha2-macroglobulin. Meth. Enzymol. 80, 737–54.
Bartl, M. M., Luckenbach, T., Bergner, O., Ullrich, O. and Koch-Brandt, C. (2001). Multiple receptors mediate apoJ-dependent clearance of cellular debris into nonprofessional phagocytes. Exp. Cell Res. 271, 130–41.
Becker, T., Hartl, F. U. and Wieland, F. (2002). CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes. J. Cell Biol. 158, 1277–85.
Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R. and Zlokovic, B. V. (2007). Transport pathways for clearance of human Alzheimer’s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb. Blood Flow. Metab. 27, 909–18.
Berkova, N., Gilbert, C., Goupil, S., Yan, J., Korobko, V. and Naccache, P. H. (1999). TNF-induced haptoglobin release from human neutrophils: pivotal role of the TNF p55 receptor. J. Immunol. 162, 6226–32.
Binder, R. J., Karimeddini, D. and Srivastava, P. K. (2001). Adjuvanticity of alpha 2-macroglobulin, an independent ligand for the heat shock protein receptor CD91. J. Immunol. 166, 4968–72.
Biringer, R. G., Amato, H., Harrington, M. G., Fonteh, A. N., Riggins, J. N. and Huhmer, A. F. (2006). Enhanced sequence coverage of proteins in human cerebrospinal fluid using multiple enzymatic digestion and linear ion trap LC-MS/MS. Brief Funct. Genomic Proteomic. 5, 144–53.
Boggs, L. N., Fuson, K. S., Baez, M., Churgay, L., McClure, D., Becker, G. and May, P. C. (1996). Clusterin (Apo J) protects against in vitro amyloid-beta (1–40) neurotoxicity. J. Neurochem. 67, 1324–7.
Botto, M., Hawkins, P. N., Bickerstaff, M. C. M., Herbert, J., Bygrave, A. E., McBride, A., Hutchinson, W. L., Tennent, G. A., Walport, M. J. and Pepys, M. B. (1997). Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat. Med. 3, 855–9.
Bowman, B. H. and Kurosky, A. (1982). Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv. Hum. Genet. 12, 189–261.
Breathnach, S. M., Bhogal, B., Dyck, R. F., De Beer, F. C., Black, M. M. and Pepys, M. B. (1981a). Immunohistochemical demonstration of amyloid P component in skin of normal subjects and patients with cutaneous amyloidosis. Br. J. Dermatol. 105, 115–24.
Breathnach, S. M., Kofler, H., Sepp, N., Ashworth, J., Woodrow, D., Pepys, M. B. and Hintner, H. (1989). Serum amyloid P component binds to cell nuclei in vitro and to in vivo deposits of extracellular chromatin in systemic lupus erythematosus. J. Exp. Med. 170, 1433–8.
Breathnach, S. M., Melrose, S. M., Bhogal, B., de Beer, F. C., Dyck, R. F., Tennent, G., Black, M. M. and Pepys, M. B. (1981b). Amyloid P component is located on elastic fibre microfibrils in normal human tissue. Nature 293, 652–4.
Brown, M. R. and Anderson, B. E. (1993). Receptor-ligand interactions between serum amyloid P component and model soluble immune complexes. J. Immunol. 151, 2087–95.
Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C. M. and Stefani, M. (2002). Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. [comment]. Nature 416, 507–11.
Calero, M., Rostagno, A., Matsubara, E., Zlokovic, B., Frangione, B. and Ghiso, J. (2000). Apolipoprotein J (clusterin) and Alzheimer’s disease. Microsc. Res. Tech. 50, 305–15.
Canet, D., Last, A. M., Tito, P., Sunde, M., Spencer, A., Archer, D. B., Redfield, C., Robinson, C. V. and Dobson, C. M. (2002). Local cooperativity in the unfolding of an amyloidogenic variant of human lysozyme. Nat. Struct. Biol. 9, 308–15.
Capiau, C., Petre, J., Van Damme, J., Puype, M. and Vandekerckhove, J. (1986). Protein-chemical analysis of pertussis toxin reveals homology between the subunits S2 and S3, between S1 and the A chains of enterotoxins of Vibrio cholerae and Escherichia coli and identifies S2 as the haptoglobin-binding subunit. FEBS Lett. 204, 336–40.
Chiesa, R., Angeretti, N., Lucca, E., Salmona, M., Tagliavini, F., Bugiani, O. and Forloni, G. (1996). Clusterin (SGP-2) induction in rat astroglial cells exposed to prion protein fragment 106–126. Eur. J. Neurosci. 8, 589–97.
Chiti, F. and Dobson, C. M. (2006). Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75, 333–66.
Chiti, F., Taddei, N., Baroni, F., Capanni, C., Stefani, M., Ramponi, G. and Dobson, C. M. (2002). Kinetic partitioning of protein folding and aggregation. Nat. Struct. Biol. 9, 137–43.
Choi-Miura, N.-H., Ihara, Y., Fukuchi, K., Takeda, M., Nakano, Y., Tobe, T. and Tomita, M. (1992). SP-40,40 is a constituent of Alzheimer’s amyloid. Acta Neuropathol. 83, 260–264.
Chromy, B. A., Nowak, R. J., Lambert, M. P., Viola, K. L., Chang, L., Velasco, P. T., Jones, B. W., Fernandez, S. J., Lacor, P. N., Horowitz, P., Finch, C. E., Krafft, G. A. and Klein, W. L. (2003). Self-assembly of Abeta(1–42) into globular neurotoxins. Biochemistry 42, 12749–60.
Chu, C. T. and Pizzo, S. V. (1993). Receptor-mediated antigen delivery into macrophages. Complexing antigen to alpha 2-macroglobulin enhances presentation to T cells. J. Immunol. 150, 48–58.
Chung, J., Yang, H., de Beus, M. D., Ryu, C. Y., Cho, K. and Colon, W. (2003). Cu/Zn superoxide dismutase can form pore-like structures. Biochem. Biophys. Res. Comm. 312, 873–6.
Cid, M. C., Grant, D. S., Hoffman, G. S., Auerbach, R., Fauci, A. S. and Kleinman, H. K. (1993). Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J. Clin. Invest. 91, 977–85.
Coker, A. R., Purvis, A., Baker, D., Pepys, M. B. and Wood, S. P. (2000). Molecular chaperone properties of serum amyloid P component. FEBS Lett. 473, 199–202.
Coria, F., Castano, E., Prelli, F., Larrondo-Lillo, M., van Duinen, S., Shelanski, M. L. and Frangione, B. (1988). Isolation and characterization of amyloid P component from Alzheimer’s disease and other types of cerebral amyloidosis. Lab. Invest. 58, 454–8.
Dahlgren, K. N., Manelli, A. M., Stine, W. B. Jr., Baker, L. K., Krafft, G. A. and LaDu, M. J. (2002). Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 277, 32046–53.
de Beer, F. C., Baltz, M. L., Holford, S., Feinstein, A. and Pepys, M. B. (1981). Fibronectin and C4-binding protein are selectively bound by aggregated amyloid P component. J. Exp. Med. 154, 1134–9.
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., Spijkers, P., Guo, H., Song, X., Lenting, P. J., Van Nostrand, W. E. and Zlokovic, B. V. (2004a). LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333–44.
Deane, R., Wu, Z. and Zlokovic, B. V. (2004b). RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood–brain barrier. Stroke 35, 2628–31.
DeMattos, R. B., Cirrito, J. R., Parsadanian, M., May, P. C., Taylor, J. W., Harmony, J. A. K., Aronow, B. J., Bales, K. R., Paul, S. M. and Holtzman, D. M. (2004). ApoE and clusterin co-operatively suppress Ab levels and deposition: evidence that apoE regulates extracellular Ab metabolism in vivo. Neuron 41, 193–202.
DeMattos, R. B., O’dell, M. A., Parsadanian, M., Taylor, J. W., Harmony, J. A. K., Bales, K. R., Paul, S. M., Aronow, B. J. and Holtzman, D. M. (2002). Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 99, 10843–8.
Dobryszycka, W. (1997). Biological functions of haptoglobin – new pieces to an old puzzle [Review]. Eur. J. Clin. Chem. Clin. Biochem. 35, 647–54.
Dobson, C. M. (1999). Protein misfolding, evolution and disease. Trends Biochem. Sci. 24, 329–32.
Donahue, J. E., Flaherty, S. L., Johanson, C. E., Duncan, J. A. 3rd, Silverberg, G. D., Miller, M. C., Tavares, R., Yang, W., Wu, Q., Sabo, E., Hovanesian, V. and Stopa, E. G. (2006). RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. Acta Neuropathol. (Berl) 112, 405–15.
Du, Y., Ni, B., Glinn, M., Dodel, R. C., Bales, K. R., Zhang, Z., Hyslop, P. A. and Paul, S. M. (1997). Alpha2-Macroglobulin as a beta-amyloid peptide-binding plasma protein. J. Neurochem.69, 299–305.
Duguid, J. R., Bohmont, C. W., Liu, N. G. and Tourtellotte, W. W. (1989). Changes in brain gene expression shared by scrapie and Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 86, 7260–4.
Dunker, A. K., Brown, C. J., Lawson, J. D., Iakoucheva, L. M. and Obradovic, Z. (2002). Intrinsic disorder and protein function. Biochemistry 41, 6573–82.
Dunker, A. K., Lawson, J. D., Brown, C. J., Williams, R. M., Romero, P., Oh, J. S., Oldfield, C. J., Campen, A. M., Ratliff, C. M., Hipps, K. W., Ausio, J., Nissen, M. S., Reeves, R., Kang, C., Kissinger, C. R., Bailey, R. W., Griswold, M. D., Chiu, W., Garner, E. C. and Obradovic, Z. (2001). Intrinsically disordered protein. J. Mol. Graph. Mod. 19, 26–59.
Dyck, R. F., Lockwood, C. M., Kershaw, M., McHugh, N., Duance, V. C., Baltz, M. L. and Pepys, M. B. (1980). Amyloid P-component is a constituent of normal human glomerular basement membrane. J. Exp. Med. 152, 1162–74.
El-Ghmati, S. M., Arredouani, M., Van Hoeyveld, E. M., Ceuppens, J. L. and Stevens, E. A. (2002). Haptoglobin interacts with the human mast cell line HMC-1 and inhibits its spontaneous proliferation. Scand. J. Immunol. 55, 352–8.
Emsley, J., White, H. E., Ohara, B. P., Oliva, G., Srinivasan, N., Tickle, I. J., Blundell, T. L., Pepys, M. B. and Wood, S. P. (1994). Structure of pentameric human serum amyloid-P component. Nature 367, 338–45.
Eustace, B. K., Sakurai, T., Stewart, J. K., Yimlamai, D., Unger, C., Zehetmeier, C., Lain, B., Torella, C., Henning, S. W., Beste, G., Scroggins, B. T., Neckers, L., Ilag, L. L. and Jay, D. G. (2004). Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness.[see comment]. Nat. Cell Biol. 6, 507–14.
Fabrizi, C., Businaro, R., Lauro, G. M. and Fumagalli, L. (2001). Role of alpha2-macroglobulin in regulating amyloid beta-protein neurotoxicity: protective or detrimental factor? J. Neurochem. 78, 406–12.
Farias, M., 3rd, Gorman, M. W., Savage, M. V. and Feigl, E. O. (2005). Plasma ATP during exercise: possible role in regulation of coronary blood flow. Am. J. Physiol. Heart Circ. Physiol. 288, H1586–90.
Fink, A. L. (1999). Chaperone-mediated protein folding. Physiol. Rev. 79, 425–49.
Freixes, M., Puig, B., Rodriguez, A., Torrejon-Escribano, B., Blanco, R. and Ferrer, I. (2004). Clusterin solubility and aggregation in Creutzfeldt-Jakob disease. Acta Neuropathol. (Berl) 108, 295–301.
French, K., Yerbury, J. J. and Wilson, M. R. (2008). The Extracellular Protease Inhibitor alpha2-Macroglobulin Also Has Chaperone Properties. Biochemistry. Published online 3 January 2008. DOI: 101021/bi701976f
Fritz, I. B., Burdzy, K., Setchell, B. and Blaschuk, O. (1983). Ram rete testis fluid contains a protein (clusterin) which influences cell–cell interactions in vitro. Biol. Reprod. 28, 1173–88.
Fukumoto, H., Asami-Odaka, A., Suzuki, N., Shimada, H., Ihara, Y. and Iwatsubo, T. (1996). Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer’s disease. Predominance of A beta 42(43) and association of A beta 40 with cored plaques. Am. J. Pathol. 148, 259–65.
Ghiso, J., Matsubara, E., Koudinov, A., Choimiura, N. H., Tomita, M., Wisniewski, T. and Frangione, B. (1993). The Cerebrospinal-fluid soluble form of Alzheimers amyloid-beta is complexed to Sp-40,40 (apolipoprotein-J), an inhibitor of the complement membrane-attack complex. Biochem. J. 293, 27–30.
Ghiso, J., Plant, G. T., Revesz, T., Wisniewski, T. and Frangione, B. (1995). Familial cerebral amyloid angiopathy (British type) with nonneuritic amyloid plaque formation may be due to a novel amyloid protein. J. Neurol. Sci. 129, 74–5.
Gorevic, P. D., Goni, F., Pons-Estel, B., Alvarez, F., Peress, N. S. and Frangione, B. (1986). Isolation and partial characterization of neurofibrillary tangles and amyloid plaque core in Alzheimer’s disease: immunohistological studies. J. Neuropathol. Exp. Neurol. 45, 647–64.
Gouin-Charnet, A., Mourad, G. and Argiles, A. (1997). Alpha 2-macroglobulin protects some of the protein constituents of dialysis-associated amyloidosis from protease degradation. Biochem. Biophys. Res. Commun. 231, 48–51.
Graversen, J. H., Madsen, M. and Moestrup, S. K. (2002). CD163: a signal receptor scavenging haptoglobin–hemoglobin complexes from plasma. Int. J. Biochem. Cell Biol. 34, 309–14.
Hamazaki, H. (1987). Ca2+-mediated association of human serum amyloid P component with heparan sulfate and dermatan sulfate. J. Biol. Chem. 262, 1456–60.
Hamazaki, H. (1995). Amyloid P component promotes aggregation of Alzheimer’s beta-amyloid peptide. Biochem. Biophys. Res. Commun. 211, 349–53.
Hammad, S. M., Ranganathan, S., Loukinova, E., Twal, W. O. and Argraves, W. S. (1997). Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2 megalin – a mechanism to prevent pathological accumulation of amyloid beta-peptide. J. Biol. Chem. 272, 18644–9.
Hatters, D. M., Wilson, M. R., Easterbrook-Smith, S. B. and Howlett, G. J. (2002). Suppression of apolipoprotein C-II amyloid formation by the extracellular chaperone, clusterin. Euro. J. Biochem. 269, 2789–94.
Hawkins, P. N., Rossor, M. N., Gallimore, J. R., Miller, B., Moore, E. G. and Pepys, M. B. (1994). Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer’s disease. Biochem. Biophys. Res. Commun. 201, 722–6.
Hay, D. G., Sathasivam, K., Tobaben, S., Stahl, B., Marber, M., Mestril, R., Mahal, A., Smith, D. L., Woodman, B. and Bates, G. P. (2004). Progressive decrease in chaperone protein levels in a mouse model of Huntington’s disease and induction of stress proteins as a therapeutic approach. Hum. Mol. Genet. 13, 1389–405.
Hensley, K., Hall, N., Subramaniam, R., Cole, P., Harris, M., Aksenov, M., Aksenova, M., Gabbita, S. P., Wu, J. F., Carney, J. M. and et al. (1995). Brain regional correspondence between Alzheimer’s disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65, 2146–56.
Hicks, P. S., Saunero-Nava, L., Du Clos, T. W. and Mold, C. (1992). Serum amyloid P component binds to histones and activates the classical complement pathway. J. Immunol. 149, 3689–94.
Hochgrebe, T., Pankhurst, G. J., Wilce, J. and Easterbrook-Smith, S. B. (2000). pH-dependent changes in the in vitro ligand-binding properties and structure of human clusterin. Biochemistry 39, 1411–9.
Hughes, S. R., Khorkova, O., Goyal, S., Knaeblein, J., Heroux, J., Riedel, N. G. and Sahasrabudhe, S. (1998). Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation. Proc. Natl. Acad. Sci. U.S.A. 95, 3275–80.
Humphreys, D., Carver, J. A., Easterbrook-Smith, S. B. and Wilson, M. R. (1999a). Clusterin has chaperone-like activity similar to that of small heat-shock proteins. J. Biol. Chem. 274, 6875–81.
Humphreys, D. T., Carver, J. A., Easterbrook-Smith, S. B. and Wilson, M. R. (1999b). Clusterin has chaperone-like activity similar to that of small heat shock proteins. J. Biol. Chem. 274, 6875–81.
Hutchinson, W. L., Noble, G. E., Hawkins, P. N. and Pepys, M. B. (1994). The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. J. Clin. Invest. 94, 1390–6.
Imber, M. J. and Pizzo, S. V. (1981). Clearance and binding of two electrophoretic forms of human alpha-2-macroglobulin. J. Biol. Chem. 256, 8134–9.
Ishii, T., Haga, S., Yagishita, S. and Tateishi, J. (1984). The presence of complements in amyloid plaques of Creutzfeldt-Jakob disease and Gerstmann-Straussler-Scheinker disease. Appl. Pathol. 2, 370–9.
Janciauskiene, S., Defrutos, P. G., Carlemalm, E., Dahlback, B. and Eriksson, S. (1995). Inhibition of Alzheimer beta-peptide fibril formation by serum amyloid P component. J. Biol. Chem. 270, 26041–4.
Jarrett, J. T. and Lansbury, P. T. Jr. (1993). Seeding “one-dimensional crystallization” of amyloid: a pathogenic mechanism in Alzheimer’s disease and scrapie? Cell 73, 1055–8.
Jenne, D. E. and Tschopp, J. (1992). Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem. Sci. 17, 154–9.
Jensen, P. E. and Sottrup-Jensen, L. (1986). Primary structure of human alpha 2-macroglobulin. Complete disulfide bridge assignment and localization of two interchain bridges in the dimeric proteinase binding unit. J. Biol. Chem. 261, 15863–9.
Jesudason, E. P., Masilamoni, J. G., Kirubagaran, R., Davis, G. D. and Jayakumar, R. (2005). The protective role of DL-alpha-lipoic acid in biogenic amines catabolism triggered by Abeta amyloid vaccination in mice. Brain Res. Bull. 65, 361–7.
Kalaria, R. N., Galloway, P. G. and Perry, G. (1991). Widespread serum amyloid P immunoreactivity in cortical amyloid deposits and the neurofibrillary pathology of Alzheimer’s disease and other degenerative disorders. Neuropathol. Appl. Neurobiol. 17, 189–201.
Kalaria, R. N. and Grahovac, I. (1990). Serum amyloid P immunoreactivity in hippocampal tangles, plaques and vessels: implications for leakage across the blood–brain barrier in Alzheimer’s disease. Brain Res. 516, 349–53.
Kapron, J. T., Hilliard, G. M., Lakins, J. N., Tenniswood, M. P. R., West, K. A., Carr, S. A. and Crabb, J. W. (1997). Identification and characterization of glycosylation sites in human serum clusterin. Protein Sci. 6, 2120–2133.
Katnik, I., Gerber, J. and Dobryszycka, W. (1987). Affino-immunoelectrophoresis of haptoglobin with wheat germ agglutinin. Diagnostic significance in ovarian carcinoma. Arch. Immunol. Therap. Experiment. 35, 547–52.
Katnik, I., Lammler, C., Guszczynski, T. and Dobryszycka, W. (1993). Quantitation of human haptoglobin by ELISA system based on streptococcal haptoglobin receptors. Arch. Immunol. Therap. Experiment. 41, 105–9.
Katzman, R., Terry, R., DeTeresa, R., Brown, T., Davies, P., Fuld, P., Renbing, X. and Peck, A. (1988). Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann. Neurol. 23, 138–44.
Keller, J. N., Huang, F. F. and Markesbery, W. R. (2000). Decreased levels of proteasome activity and proteasome expression in aging spinal cord. Neuroscience 98, 149–56.
Kelly, J. W. (1998). The environmental dependency of protein folding best explains prion and amyloid diseases. Proc. Natl. Acad. Sci. U.S.A. 95, 930–2.
Kida, E., Choi-Miura, N. H. and Wisniewski, K. E. (1995). Deposition of apolipoproteins E and J in senile plaques is topographically determined in both Alzheimer’s disease and Down’s syndrome brain. Brain Res. 685, 211–6.
Kimura, T., Tani, S., Matsumoto Yi, Y. and Takeda, T. (2001). Serum amyloid P component is the Shiga toxin 2-neutralizing factor in human blood. J. Biol. Chem. 276, 41576–9.
Kinoshita, C. M., Gewurz, A. T., Siegel, J. N., Ying, S. C., Hugli, T. E., Coe, J. E., Gupta, R. K., Huckman, R. and Gewurz, H. (1992). A protease-sensitive site in the proposed Ca(2+)-binding region of human serum amyloid P component and other pentraxins. Protein Sci. 1, 700–9.
Kirkitadze, M. D., Bitan, G. and Teplow, D. B. (2002). Paradigm shifts in Alzheimer’s disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J. Neurosci. Res. 69, 567–77.
Klimaschewski, L., Obermuller, N. and Witzgall, R. (2001). Regulation of clusterin expression following spinal cord injury. Cell Tissue Res. 306, 209–16.
Kounnas, M. Z., Haudenschild, C. C., Strickland, D. K. and Argraves, W. S. (1994). Immunological localization of glycoprotein 330, low density lipoprotein receptor related protein and 39 kDa receptor associated protein in embryonic mouse tissues. In Vivo 8, 343–51.
Kumita, J. R., Poon, S., Caddy, G. L., Hagan, C. L., Dumoulin, M., Yerbury, J. J., Stewart, E. M., Robinson, C. V., Wilson, M. R. and Dobson, C. M. (2007). The extracellular chaperone clusterin potently inhibits human lysozyme amyloid formation by interacting with prefibrillar species. J. Mol. Biol. 369, 157–67.
Kurdowska, A., Alden, S. M., Noble, J. M., Stevens, M. D. and Carr, F. K. (2000). Involvement of alpha-2-macroglobulin receptor in clearance of interleukin 8-alpha-2-macroglobulin complexes by human alveolar macrophages. Cytokine 12, 1046–53.
Langlois, M., Delanghe, J., Philippe, J., Ouyang, J., Bernard, D., De Buyzere, M., Van Nooten, G. and Leroux-Roels, G. (1997). Distribution of lymphocyte subsets in bone marrow and peripheral blood is associated with haptoglobin type. Binding of haptoglobin to the B-cell lectin CD22. Euro. J. Clin. Chem. Clin. Biochem. 35, 199–205.
Laporte, V., Lombard, Y., Levy-Benezra, R., Tranchant, C., Poindron, P. and Warter, J. M. (2004). Uptake of Abeta 1-40- and Abeta 1-42-coated yeast by microglial cells: a role for LRP. J. Leukoc. Biol. 76, 451–61.
Lashley, T., Holton, J. L., Verbeek, M. M., Rostagno, A., Bojsen-Moller, M., David, G., van Horssen, J., Braendgaard, H., Plant, G., Frangione, B., Ghiso, J. and Revesz, T. (2006). Molecular chaperons, amyloid and preamyloid lesions in the BRI2 gene-related dementias: a morphological study. Neuropathol. Appl. Neurobiol. 32, 492–504.
Lashuel, H. A., Hartley, D. M., Petre, B. M., Wall, J. S., Simon, M. N., Walz, T. and Lansbury, P. T., Jr. (2003). Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. J. Mol. Biol. 332, 795–808.
Laskey, R. A., Honda, B. M., Mills, A. D. and Finch, J. T. (1978). Nucleosomes are assembled by an acidic protein which binds histones and transfers them to DNA. Nature 275, 416–20.
Lauer, D., Reichenbach, A. and Birkenmeier, G. (2001). Alpha 2-macroglobulin-mediated degradation of amyloid beta 1–42: a mechanism to enhance amyloid beta catabolism. Exp. Neurol. 167, 385–92.
Lauro, G. M., Fabrizi, C., Businaro, R., Fumagalli, L., Torelli, S. and Gremo, F. (1992). Human astroglial but not microglial cells synthesize alpha 2-macroglobulin in vitro. Ital. J. Neurol. Sci. 13, 661–5.
Lee, J. P., Gerin, C., Bindokas, V. P., Miller, R., Ghadge, G. and Roos, R. P. (2002). No correlation between aggregates of Cu/Zn superoxide dismutase and cell death in familial amyotrophic lateral sclerosis. J. Neurochem. 82, 1229–38.
Licastro, F., Morini, M. C., Polazzi, E. and Davis, L. J. (1995). Increased serum alpha 1-antichymotrypsin in patients with probable Alzheimer’s disease: an acute phase reactant without the peripheral acute phase response. J. Neuroimmunol. 57, 71–5.
Lidstrom, A. M., Hesse, C., Rosengren, L., Fredman, P., Davidsson, P. and Blennow, K. (2001). Normal levels of clusterin in cerebrospinal fluid in Alzheimer’s disease, and no change after acute ischemic stroke. J. Alzheimers Dis. 3, 435–442.
Lim, S. K. (2001). Consequences of haemolysis without haptoglobin. Redox Report 6, 375–378.
Lim, S. K., Kim, H., Bin Ali, A., Lim, Y. K., Wang, Y., Chong, S. M., Costantini, F. and Baumman, H. (1998). Increased susceptibility in Hp knockout mice during acute hemolysis. Blood 92, 1870–7.
Louagie, H., Delanghe, J., Desombere, I., De Buyzere, M., Hauser, P. and Leroux-Roels, G. (1993). Haptoglobin polymorphism and the immune response after hepatitis B vaccination. Vaccine 11, 1188–90.
Mahon, M. G., Lindstedt, K. A., Hermann, M., Nimpf, J. and Schneider, W. J. (1999). Multiple involvement of clusterin in chicken ovarian follicle development – Binding to two oocyte-specific members of the low density lipoprotein receptor gene family. J. Biol. Chem. 274, 4036–4044.
Marcon, G., Plakoutsi, G., Canale, C., Relini, A., Taddei, N., Dobson, C. M., Ramponi, G. and Chiti, F. (2005). Amyloid formation from HypF-N under conditions in which the protein is initially in its native state. J. Mol. Biol. 347, 323–35.
Matsubara, E., Frangione, B. and Ghiso, J. (1995). Characterization of apolipoprotein J-Alzheimer’s a beta interaction. J. Biol. Chem. 270, 7563–7.
Matsubara, E., Soto, C., Governale, S., Frangione, B. and Ghiso, J. (1996). Apolipoprotein J and Alzheimer’s amyloid beta solubility. Biochem. J. 316, 671–9.
May, P. C., Johnson, S. A., Poirier, J., Lampert-Etchells, M. and Finch, C. E. (1989). Altered gene expression in Alzheimer’s disease brain tissue. Can J. Neurol. Sci. 16, 473–6.
McHattie, S. and Edington, N. (1999). Clusterin prevents aggregation of neuropeptide 106–126 in vitro. Biochem. Biophys. Res. Commun. 259, 336–40.
Mettenburg, J. M., Webb, D. J. and Gonias, S. L. (2002). Distinct binding sites in the structure of alpha 2-macroglobulin mediate the interaction with beta-amyloid peptide and growth factors. J. Biol. Chem. 277, 13338–45.
Michel, D., Chatelain, G., North, S. and Brun, G. (1997). Stress-induced transcription of the clusterin/apoJ gene. Biochem. J. 328, 45–50.
Mirzabekov, T. A., Lin, M. C. and Kagan, B. L. (1996). Pore formation by the cytotoxic islet amyloid peptide amylin. J. Biol. Chem. 271, 1988–92.
Motomiya, Y., Ando, Y., Haraoka, K., Sun, X., Iwamoto, H., Uchimura, T. and Maruyama, I. (2003). Circulating level of alpha2-macroglobulin-beta2-microglobulin complex in hemodialysis patients. Kidney Int. 64, 2244–52.
Muchowski, P. J. and Wacker, J. L. (2005). Modulation of neurodegeneration by molecular chaperones. Nat. Rev. Neurosci. 6, 11–22.
Murphy, B., Kirszbaum, L., Walker, I. D. and d’Apice, J. F. (1988). SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis. J. Clin. Invest. 81, 1858–64.
Narita, M., Holtzman, D. M., Schwartz, A. L. and Bu, G. (1997). Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J. Neurochem. 69, 1904–11.
Nicoletti, G., Annesi, G., Tomaino, C., Spadafora, P., Pasqua, A. A., Annesi, F., Serra, P., Caracciolo, M., Messina, D., Zappia, M. and Quattrone, A. (2002). No evidence of association between the alpha-2 macroglobulin gene and Parkinson’s disease in a case-control sample. Neurosci. Lett. 328, 65–7.
Nishida, K., Quantock, A. J., Dota, A., Choi-Miura, N. H. and Kinoshita, S. (1999). Apolipoproteins J and E co-localise with amyloid in gelatinous drop-like and lattice type I corneal dystrophies. Br. J. Ophthalmol. 83, 1178–82.
Nizard, P., Tetley, S., Le Drean, Y., Watrin, T., Le Goff, P., Wilson, M. R. and Michel, D. (2007). Stress-induced retrotranslocation of clusterin/ApoJ into the cytosol. Traffic 8, 554–65.
Oda, T., Pasinetti, G. M., Osterburg, H. H., Anderson, C., Johnson, S. A. and Finch, C. E. (1994). Purification and characterization of Brain Clusterin. Bioch. Biophys. Res. Commun. 204, 1131–6.
Oda, T., Wals, P., Osterburg, H. H., Johnson, S. A., Pasinetti, G. M., Morgan, T. E., Rozovsky, I., Stine, W. B., Snyder, S. W. and Holzman, T. F. (1995). Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1–42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp. Neurol. 136, 22–31.
Oh, S. K., Pavlotsky, N. and Tauber, A. I. (1990). Specific binding of haptoglobin to human neutrophils and its functional consequences. J. Leuk. Biol. 47, 142–8.
Pavlicek, Z. and Ettrich, R. (1999). Chaperone- like activity of human haptoglobin: similarity with alpha-crystallin. Collect. Czech. Chem. Commun 64, 717–25.
Pepys, M. B. (1995). Amyloidosis. Samter’s immunological diseases. M. M. Frank (ed.). Boston, USA, Little, Brown & Co: 637–55.
Pepys, M. B., Baltz, M., Gomer, K., Davies, A. J. and Doenhoff, M. (1979a). Serum amyloid P-component is an acute-phase reactant in the mouse. Nature 278, 259–61.
Pepys, M. B. and Butler, P. J. (1987). Serum amyloid P component is the major calcium-dependent specific DNA binding protein of the serum. Bioch. Biophys. Res. Commun. 148, 308–13.
Pepys, M. B., Dash, A. C., Markham, R. E., Thomas, H. C., Williams, B. D. and Petrie, A. (1978). Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin. Exp. Immunol. 32, 119–24.
Pepys, M. B., Dyck, R. F., de Beer, F. C., Skinner, M. and Cohen, A. S. (1979b). Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin. Exp. Immunol. 38, 284–93.
Pepys, M. B., Rademacher, T. W., Amatayakul-Chantler, S., Williams, P., Noble, G. E., Hutchinson, W. L., Hawkins, P. N., Nelson, S. R., Gallimore, J. R., Herbert, J. and et al. (1994). Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc. Natl. Acad. Sci. U.S.A. 91, 5602–6.
Perlmutter, L. S., Barron, E., Myers, M., Saperia, D. and Chui, H. C. (1995). Localization of amyloid P component in human brain: vascular staining patterns and association with Alzheimer’s disease lesions. J. Comp. Neurol. 352, 92–105.
Piubelli, C., Fiorini, M., Zanusso, G., Milli, A., Fasoli, E., Monaco, S. and Righetti, P. G. (2006). Searching for markers of Creutzfeldt-Jakob disease in cerebrospinal fluid by two-dimensional mapping. Proteomics 6 (Suppl 1), S256–61.
Poon, S., Rybchyn, M. S., Easterbrook-Smith, S. B., Carver, J. A., Pankhurst, G. J. and Wilson, M. R. (2002). Mildly Acidic pH activates the extracellular molecular chaperone clusterin. J. Biol. Chem. 277, 39532–40.
Poon, S., Rybchyn, M. S., Easterbrook-Smith, S. B., Carver, J. A. and Wilson, M. R. (2000). Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state. Biochemistry 39, 15953–60.
Powers, J. M., Schlaepfer, W. W., Willingham, M. C. and Hall, B. J. (1981). An immunoperoxidase study of senile cerebral amyloidosis with pathogenetic considerations. J. Neuropathol. Exp. Neurol. 40, 592–612.
Qiu, W. Q., Borth, W., Ye, Z., Haas, C., Teplow, D. B. and Selkoe, D. J. (1996). Degradation of amyloid beta-protein by a serine protease-alpha2-macroglobulin complex. J. Biol. Chem. 271, 8443–51.
Ross, G. D. (2000). Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein. Critical Rev. Immunol. 20, 197–222.
Rostagno, A., Lashley, T., Ng, D., Meyerson, J., Braendgaard, H., Plant, G., Bojsen-Moller, M., Holton, J., Frangione, B., Revesz, T. and Ghiso, J. (2007). Preferential association of serum amyloid P component with fibrillar deposits in familial British and Danish dementias: similarities with Alzheimer’s disease. J. Neurol. Sci. 257, 88–96.
Sakaguchi, H., Miyagi, M., Shadrach, K. G., Rayborn, M. E., Crabb, J. W. and Hollyfield, J. G. (2002). Clusterin is present in drusen in age-related macular degeneration. Exp. Eye. Res. 74, 547–9.
Sasaki, K., Doh-ura, K., Ironside, J. W. and Iwaki, T. (2002a). Increased clusterin (apolipoprotein J) expression in human and mouse brains infected with transmissible spongiform encephalopathies. Acta Neuropathol. 103, 199–208.
Sasaki, K., Doh-ura, K., Wakisaka, Y. and Iwaki, T. (2002b). Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with alpha-synucleinopathies. Acta Neuropathol. (Berl) 104, 225–30.
Savage, M. J., Trusko, S. P., Howland, D. S., Pinsker, L. R., Mistretta, S., Reaume, A. G., Greenberg, B. D., Siman, R. and Scott, R. W. (1998). Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J. Neurosci. 18, 1743–52.
Savaskan, E., Olivieri, G., Meier, F., Seifritz, E., Wirz-Justice, A. and Muller-Spahn, F. (2003). Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity. Gerontology 49, 380–3.
Schlotzer-Schrehardt, U. M., Koca, M. R., Naumann, G. O. and Volkholz, H. (1992). Pseudoexfoliation syndrome. Ocular manifestation of a systemic disorder? Arch Ophthalmol. 110, 1752–6.
Sen, J. W. and Heegaard, N. H. (2002). Serum amyloid p component does not circulate in complex with C4-binding protein, fibronectin or any other major protein ligand. Scand. J. Immunol. 56, 85–93.
Serpell, L. C. (2000). Alzheimer’s amyloid fibrils: structure and assembly. Biochim. Biophys. Acta 1502, 16–30.
Serpell, L. C., Sunde, M., Benson, M. D., Tennent, G. A., Pepys, M. B. and Fraser, P. E. (2000). The protofilament substructure of amyloid fibrils. J. Mol. Biol. 300, 1033–39.
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J. and Zlokovic, B. V. (2000). Clearance of Alzheimer’s amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood–brain barrier. J. Clin. Invest. 106, 1489–99.
Shorter, J. and Lindquist, S. (2004). Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. Science 304, 1793–7.
Snellman, O. and Sylven, B. (1967). Haptoglobin acting as a natural inhibitor of cathepsin B activity. Nature 216, 1033.
Sobek, O. and Adam, P. (2003). On S. Seygert, V. Kunzmann, N. Schwertfeger, H. C. Koch, A. Faulstich: determinants of lumbar CSF protein concentration. J. Neurol. 250, 371–2. author reply 372.
Sorensen, I. J., Andersen, O., Nielsen, E. H. and Svehag, S. E. (1995). Native human serum amyloid P component is a single pentamer. Scand. J. Immunol. 41, 263–267.
Sorensen, I. J., Nielsen, E. H., Andersen, O., Danielsen, B. and Svehag, S. E. (1996). Binding of complement proteins C1q and C4bp to serum amyloid P component (SAP) in solid contra liquid phase. Scand. J. Immunol. 44, 401–7.
Sottrup-Jensen, L. (1989). Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J. Biol. Chem. 264, 11539–42.
Sousa, M. M., Cardoso, I., Fernandes, R., Guimaraes, A. and Saraiva, M. J. (2001). Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am. J. Pathol. 159, 1993–2000.
Srivastava, P. (2002). Roles of heat-shock proteins in innate and adaptive immunity. Nat. Rev. Immunol. 2, 185–94.
Stefani, M. and Dobson, C. M. (2003). Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 81, 678–99.
Stewart, E. M., Aquilina, J. A., Easterbrook-Smith, S. B., Murphy-Durland, D., Jacobsen, C., Moestrup, S. and Wilson, M. R. (2007). Effects of glycosylation on the structure and function of the extracellular chaperone clusterin. Biochemistry 46, 1412–22.
Stix, B., Leber, M., Bingemer, P., Gross, C., Ruschoff, J., Fandrich, M., Schorderet, D. F., Vorwerk, C. K., Zacharias, M., Roessner, A. and Rocken, C. (2005). Hereditary lattice corneal dystrophy is associated with corneal amyloid deposits enclosing C-terminal fragments of keratoepithelin. Invest. Ophthalmol. Vis. Sci. 46, 1133–9.
Sunde, M. and Blake, C. (1997). The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv. Protein Chem. 50, 123–59.
Swanson, S. J., Christner, R. B. and Mortensen, R. F. (1992). Human serum amyloid P-component (SAP) selectively binds to immobilized or bound forms of C-reactive protein (CRP). Biochim. Biophys. Acta 1160, 309–16.
Taddei, K., Clarnette, R., Gandy, S. E. and Martins, R. N. (1997). Increased plasma apolipoprotein E (apoE) levels in Alzheimer’s disease. Neurosci. Lett. 223, 29–32.
Tennent, G. A., Lovat, L. B. and Pepys, M. B. (1995). Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc. Natl. Acad. Sci. U.S.A. 92, 4299–303.
van Gestel, J. and de Leeuw, S. W. (2007). The formation of fibrils by intertwining of filaments: model and application to amyloid Abeta protein. Biophys. J. 92, 1157–63.
Van Gool, D., De Strooper, B., Van Leuven, F., Triau, E. and Dom, R. (1993). Alpha2-macroglobulin expression in neuritic-type plaques in patients with Alzheimer’s disease. Neurobiol. Aging 14, 233–37.
Volles, M. J. and Lansbury, P. T. Jr. (2003). Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson’s disease. Biochemistry 42, 7871–8.
Wagner, L., Gessl, A., Parzer, S. B., Base, W., Waldhausl, W. and Pasternack, M. S. (1996). Haptoglobin phenotyping by newly developed monoclonal antibodies. Demonstration of haptoglobin uptake into peripheral blood neutrophils and monocytes. J. Immunol. 156, 1989–96.
Westerheide, S. D. and Morimoto, R. I. (2005). Heat shock response modulators as therapeutic tools for diseases of protein conformation. J. Biol. Chem. 280, 33097–100.
Whittall, T., Wang, Y., Kelly, C. G., Thomson, R., Sanderson, J., Lomer, M., Soon, S. Y., Bergmeier, L. A., Singh, M. and Lehner, T. (2006). Tumour necrosis factor-alpha production stimulated by heat shock protein 70 and its inhibition in circulating dendritic cells and cells eluted from mucosal tissues in Crohn’s disease. Clin. Exp. Immunol. 143, 550–9.
Williams, K. M. and Marshall, T. (2001). Protein concentration of cerebrospinal fluid by precipitation with Pyrogallol Red prior to sodium dodecyl sulphate-polyacrylamide gel electrophoresis. J. Biochem. Biophys. Methods 47, 197–207.
Wilson, M. R. and Easterbrook-Smith, S. B. (2000). Clusterin is a secreted mammalian chaperone. Trends Biochem. Sci. 25, 95–8.
Wood, S. P., Oliva, G., O’Hara, B. P., White, H. E., Blundell, T. L., Perkins, S. J., Sardharwalla, I. and Pepys, M. B. (1988). A pentameric form of human serum amyloid P component. Crystallization, X-ray diffraction and neutron scattering studies. J. Mol. Biol. 202, 169–73.
Yang, G. C., Nieto, R., Stachura, I. and Gallo, G. R. (1992). Ultrastructural immunohistochemical localization of polyclonal IgG, C3, and amyloid P component on the congo red-negative amyloid-like fibrils of fibrillary glomerulopathy. Am. J. Pathol. 141, 409–19.
Yerbury, J. J., Poon, S., Meehan, S., Thompson, B., Kumita, J. R., Dobson, C. M. and Wilson, M. R. (2007). The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J. 21, 2312–22.
Yerbury, J. J., Rybchyn, M. S., Easterbrook-Smith, S. B., Henriques, C. and Wilson, M. R. (2005a). The acute phase protein haptoglobin is a mammalian extracellular chaperone with an action similar to clusterin. Biochemistry 44, 10914–25.
Yerbury, J. J., Stewart, E. M., Wyatt, A. R. and Wilson, M. R. (2005b). Quality control of protein folding in extracellular space. EMBO Rep. 6, 1131–6.
Yong, W., Lomakin, A., Kirkitadze, M. D., Teplow, D. B., Chen, S. H. and Benedek, G. B. (2002). Structure determination of micelle-like intermediates in amyloid beta -protein fibril assembly by using small angle neutron scattering. Proc. Natl. Acad. Sci. U.S.A. 99, 150–4.
Zahedi, K. (1996). Characterization of the binding of serum amyloid P to type IV collagen. [erratum appears in J. Biol. Chem. 1996 Aug 9; 271(32):19632]. J. Biol. Chem. 271, 14897–902.
Zahedi, K. (1997). Characterization of the binding of serum amyloid P to laminin. J. Biol. Chem. 272, 2143–8.
Zenkel, M., Kruse, F. E., Junemann, A. G., Naumann, G. O. and Schlotzer-Schrehardt, U. (2006). Clusterin deficiency in eyes with pseudoexfoliation syndrome may be implicated in the aggregation and deposition of pseudoexfoliative material. Invest. Ophthalmol. Vis. Sci. 47, 1982–90.
Zlokovic, B. V. (1996). Cerebrovascular transport of Alzheimer’s amyloid beta and apolipoproteins J and E: possible anti-amyloidogenic role of the blood–brain barrier. Life Sci. 59, 1483–97.
Zlokovic, B. V., Yamada, S., Holtzman, D., Ghiso, J. and Frangione, B. (2000). Clearance of amyloid beta-peptide from brain: transport or metabolism? Nat. Med. 6, 718–9.
Zwain, I. H., Grima, J. and Cheng, C. Y. (1994). Regulation of clusterin secretion and mRNA expression in astrocytes by cytokines. Mol. Cell. Neurosci. 5, 229–237.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Wilson, M.R., Yerbury, J.J., Poon, S. (2008). Extracellular Chaperones and Amyloids. In: Asea, A.A., Brown, I.R. (eds) Heat Shock Proteins and the Brain: Implications for Neurodegenerative Diseases and Neuroprotection. Heat Shock Proteins, vol 3. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-8231-3_15
Download citation
DOI: https://doi.org/10.1007/978-1-4020-8231-3_15
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-8230-6
Online ISBN: 978-1-4020-8231-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)